Ahmed Said Kadah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Said Kadah has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Hassan Nouh
Department of Dermatology and Venereology, Al-Azhar University, Cairo, Egypt
3 shared publications - Marwa Said
Dermatology and Venereology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt
2 shared publications Ahmed A. Suliman
Department of Dermatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publicationAhmed Abdelkader Mohamed
Department of Dermatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publicationAhmed R. Elshahid
Department of Dermatology Venereology and Andrology Faculty of Medicine of Al‐Azhar University Cairo Egypt
1 shared publicationAhmed Rashad Elshahid
Dermatology, Venereology and Andrology department, Faculty of Medicine Al‐Azhar University Cairo Egypt
1 shared publication
Latest Publications
- 1 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-9
Fractional CO2 laser with topical insulin versus PRP for atrophic acne scars: a randomized split-face study
Atrophic acne scarring is a prevalent problem that has been treated with a variety of procedures, each with various degrees of success. For better results, combined regimens of treatment are recommended. Our aim was to compare the efficacy of topical insulin against topical platelet-rich plasma (PRP) as an adjunct treatment to fractional CO2 laser for atrophic acne scars. The study comprised 30 patients with atrophic acne scars. All patients underwent four sessions of fractional CO2 laser on both sides of the face at one-month intervals, followed by topical PRP treatment on one side of the face and topical insulin on the other. Two non-treating dermatologists used the Acne Scar Assessment Scale (ASAS) to assess the outcome. At their last follow-up appointment, patients were asked to assess their improvement on each side of the face in a percentage from 0 to 100%. Prior to treatment, there was no difference in the ASAS scores between the two sides of the face. One month after the last treatment session, ASAS scores improved significantly on both sides of the face. No significant difference (p = 0.794) between both sides were detected. Both techniques helped to improve atrophic acne scars and may have a synergistic outcome regarding efficacy and safety.
- 1 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-9
Fractional CO2 laser with topical insulin versus PRP for atrophic acne scars: a randomized split-face study
Atrophic acne scarring is a prevalent problem that has been treated with a variety of procedures, each with various degrees of success. For better results, combined regimens of treatment are recommended. Our aim was to compare the efficacy of topical insulin against topical platelet-rich plasma (PRP) as an adjunct treatment to fractional CO2 laser for atrophic acne scars. The study comprised 30 patients with atrophic acne scars. All patients underwent four sessions of fractional CO2 laser on both sides of the face at one-month intervals, followed by topical PRP treatment on one side of the face and topical insulin on the other. Two non-treating dermatologists used the Acne Scar Assessment Scale (ASAS) to assess the outcome. At their last follow-up appointment, patients were asked to assess their improvement on each side of the face in a percentage from 0 to 100%. Prior to treatment, there was no difference in the ASAS scores between the two sides of the face. One month after the last treatment session, ASAS scores improved significantly on both sides of the face. No significant difference (p = 0.794) between both sides were detected. Both techniques helped to improve atrophic acne scars and may have a synergistic outcome regarding efficacy and safety.
- Open Access
- 22 January 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (5) , 1647-1657
Topical niacinamide (Nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study
Background: Cutaneous lupus erythematosus is an umbrella term for a group of autoimmune connective tissue disorders affecting the skin. Discoid lupus erythematosus (DLE) is the chronic condition and most common form of cutaneous lupus erythematosus.Aims: Current therapies of DLE are challenging and not completely satisfactory, highly expensive, off‐label, or poorly available (like antimalarials due to COVID‐19 outbreaks). Nicotinamide, also called niacinamide, is a water‐soluble form of vitamin B3 (niacin). Its multiple effects let us think that nicotinamide could be a therapy for lupus‐associated skin lesions.Methods: We performed a prospective randomized double‐blind clinical trial on 60 subjects diagnosed with Discoid lupus erythematosus using topical Nicotinamide 2% and 4% preparations in form of cream and gel on skin and scalp lesions. Control group was included using only cream/gel base as placebo control.Results: Obtained data showed that topical Nicotinamide can be used for the treatment of DLE as adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Topical 4% Nicotinamide is superior to 2% preparation in response but associated with a higher incidence of irritation.Conclusion: Topical Nicotinamide can be used for the treatment of DLE as an adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Further trials with long‐term therapy, follow‐up period, and bigger sample sizes are required.
- 22 January 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (5) , 1647-1657
Open AccessTopical niacinamide (Nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study
Background: Cutaneous lupus erythematosus is an umbrella term for a group of autoimmune connective tissue disorders affecting the skin. Discoid lupus erythematosus (DLE) is the chronic condition and most common form of cutaneous lupus erythematosus.Aims: Current therapies of DLE are challenging and not completely satisfactory, highly expensive, off‐label, or poorly available (like antimalarials due to COVID‐19 outbreaks). Nicotinamide, also called niacinamide, is a water‐soluble form of vitamin B3 (niacin). Its multiple effects let us think that nicotinamide could be a therapy for lupus‐associated skin lesions.Methods: We performed a prospective randomized double‐blind clinical trial on 60 subjects diagnosed with Discoid lupus erythematosus using topical Nicotinamide 2% and 4% preparations in form of cream and gel on skin and scalp lesions. Control group was included using only cream/gel base as placebo control.Results: Obtained data showed that topical Nicotinamide can be used for the treatment of DLE as adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Topical 4% Nicotinamide is superior to 2% preparation in response but associated with a higher incidence of irritation.Conclusion: Topical Nicotinamide can be used for the treatment of DLE as an adjuvant to other treatment regimens with good cosmetic results and minimal side effects. Further trials with long‐term therapy, follow‐up period, and bigger sample sizes are required.
- Open Access
- 30 November 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (2) , 529-533
Efficacy of Jessener solution versus intralesional steroid in treatment of alopecia areata
- 30 November 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (2) , 529-533
Open AccessEfficacy of Jessener solution versus intralesional steroid in treatment of alopecia areata
- 3 August 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (9) , e15734
Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study)
To assess and evaluate the efficacy and safety of nicotinamide 4% topical formulation for the treatment of mild to moderate psoriasis. This study was conducted on 60 patients aged 18-65 years, with mild to moderate psoriasis vulgaris. Nicotinamide 4% in a cold cream base was used twice daily for 12 weeks. Nicotinamide 4% topical treatment shows satisfactory results, more in males than in females. Some patients report disturbing irritation (burning, itching, and redness) upon the usage of topical nicotinamide treatment and were advised to wash out the treated area after 1 h of cream application, which solved the issue. No other adverse effects of treatment were reported by patients during the study period. Unicentral base, a limited amount of sample size, and 12 weeks duration of therapy and follow-up period, which may not be sufficient to demonstrate the complete therapeutic properties and side effects of using nicotinamide as a long-term treatment for psoriasis. This study reveals statistically reliable evidence of the positive impact of topical 4% nicotinamide preparation used alone on the treatment of psoriasis with minimal side effects. Thus, we can conclude that topical nicotinamide preparation may be a good adjuvant to the current treatment regimens used alone or alternate currently used topical therapeutical regimens if used in combination.
- 3 August 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (9) , e15734
Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study)
To assess and evaluate the efficacy and safety of nicotinamide 4% topical formulation for the treatment of mild to moderate psoriasis. This study was conducted on 60 patients aged 18-65 years, with mild to moderate psoriasis vulgaris. Nicotinamide 4% in a cold cream base was used twice daily for 12 weeks. Nicotinamide 4% topical treatment shows satisfactory results, more in males than in females. Some patients report disturbing irritation (burning, itching, and redness) upon the usage of topical nicotinamide treatment and were advised to wash out the treated area after 1 h of cream application, which solved the issue. No other adverse effects of treatment were reported by patients during the study period. Unicentral base, a limited amount of sample size, and 12 weeks duration of therapy and follow-up period, which may not be sufficient to demonstrate the complete therapeutic properties and side effects of using nicotinamide as a long-term treatment for psoriasis. This study reveals statistically reliable evidence of the positive impact of topical 4% nicotinamide preparation used alone on the treatment of psoriasis with minimal side effects. Thus, we can conclude that topical nicotinamide preparation may be a good adjuvant to the current treatment regimens used alone or alternate currently used topical therapeutical regimens if used in combination.
- 4 February 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15358
Comparative study of the use of fractional CO 2 laser versus the use of liquid nitrogen cryotherapy in the treatment of alopecia areata in a sample of the Egyptian population
Background Alopecia areata (AA) is an autoimmune disease that is represented as patches of hair loss, FractionalCo2 laser and Cryotherapy are used to stimulate hair growth in patients of AA. Aim evaluation of fractional co2 laser effect versus liquid nitrogen cryotherapy in the treatment of Alopecia Areata. Methods Eighty patients presented with patches of AA. The first group consisted of 40 patients was treated with fractional co2 laser, the second group also 40 patients was treated with cryotherapy. The efficacy of the treatment was statistically evaluated. Results A positive therapeutic response was noted in most patients By trichoscopy at the end of treatment, there was a decrease in exclamation mark hairs, yellow dots, black dots, broken hairs, and an increase in short vellus hair and circle hair of patients compared to baseline and control. No serious side effects were seen. Conclusion Fractional co2 laser and Liquid nitrogen cryotherapy is considered a promising, safe, and effective treatment modality with the better result with co2 laser
- 4 February 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (4) , e15358
Comparative study of the use of fractional CO 2 laser versus the use of liquid nitrogen cryotherapy in the treatment of alopecia areata in a sample of the Egyptian population
Background Alopecia areata (AA) is an autoimmune disease that is represented as patches of hair loss, FractionalCo2 laser and Cryotherapy are used to stimulate hair growth in patients of AA. Aim evaluation of fractional co2 laser effect versus liquid nitrogen cryotherapy in the treatment of Alopecia Areata. Methods Eighty patients presented with patches of AA. The first group consisted of 40 patients was treated with fractional co2 laser, the second group also 40 patients was treated with cryotherapy. The efficacy of the treatment was statistically evaluated. Results A positive therapeutic response was noted in most patients By trichoscopy at the end of treatment, there was a decrease in exclamation mark hairs, yellow dots, black dots, broken hairs, and an increase in short vellus hair and circle hair of patients compared to baseline and control. No serious side effects were seen. Conclusion Fractional co2 laser and Liquid nitrogen cryotherapy is considered a promising, safe, and effective treatment modality with the better result with co2 laser